Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study

(2017) Anne Godier et al.   EUROPEAN HEART JOURNAL

Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)

(2017) R. C. Gosselin et al.   Hamostaseologie

Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice

(2017) C. Wright et al.   International Journal of Laboratory Hematology

International Reports of Unexpected Low Plasma Concentrations of Dabigatran Suggest That More Frequent Measurements Will Add Value

(2017) Marilina Castellano et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Laboratory Assessment of Direct Oral Anticoagulants

(2017) Robert Gosselin et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels

(2017) Lina Sabor et al.   THROMBOSIS RESEARCH

Impact of rivaroxaban on point-of-care assays

(2017) Pierre Fontana et al.   THROMBOSIS RESEARCH

Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

(2017) David J. Seiffge et al.   Journal of Stroke

Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation

(2017) John W. Eikelboom et al.   JAMA Cardiology

Urgent Need to Measure Effects of Direct Oral Anticoagulants: Table.

(2016) Jeffrey I. Weitz et al.   CIRCULATION

Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging

(2016) Sarah Lessire et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays

(2016) R. Gosselin et al.   International Journal of Laboratory Hematology

The laboratory's 2015 perspective on direct oral anticoagulant testing

(2016) R. C. Gosselin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

To measure or not to measure direct oral anticoagulants before surgery or invasive procedures

(2016) A. Tripodi   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply

(2016) A. Tripodi   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment

(2016) A. C. Spyropoulos et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

(2016) J. H. Levy et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure

(2016) J. D. Douketis et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

(2016) S. Testa et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke

(2016) David J. Seiffge et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

(2016) Roslyn Bonar et al.   PATHOLOGY

Periprocedural Management of Direct Oral Anticoagulants

(2016) James D. Douketis et al.   REGIONAL ANESTHESIA AND PAIN MEDICINE

Direct Oral Anticoagulants

(2016) Honorio T. Benzon et al.   REGIONAL ANESTHESIA AND PAIN MEDICINE

Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests

(2016) Sarah Lessire et al.   REGIONAL ANESTHESIA AND PAIN MEDICINE

Edoxaban: Impact on routine and specific coagulation assays

(2016) Bernard Chatelain et al.   THROMBOSIS AND HAEMOSTASIS

Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism

(2016) Philip S. Wells et al.   THROMBOSIS AND HAEMOSTASIS

Lupus-anticoagulant testing at NOAC trough levels

(2016) Franz Ratzinger et al.   THROMBOSIS AND HAEMOSTASIS

Direct oral anticoagulant drug level testing in clinical practice: A single institution experience

(2016) Karlyn Martin et al.   THROMBOSIS RESEARCH

Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?

(2016) Jonathan Douxfils et al.   TRAC-TRENDS IN ANALYTICAL CHEMISTRY

Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

(2015) Giuseppe Lippi et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Dose tailoring of dabigatran etexilate: obvious or excessive?

(2015) Jonathan Douxfils et al.   Expert Opinion On Drug Safety

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

(2015) Christian T Ruff et al.   LANCET

The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

(2015) Roslyn Bonar et al.   PATHOLOGY

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

(2015) Samer Narouze et al.   REGIONAL ANESTHESIA AND PAIN MEDICINE

Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors

(2015) Giuseppe Lippi et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Estimation of dabigatran plasma concentrations in the perioperative setting

(2015) Anne-Sophie Dincq et al.   THROMBOSIS AND HAEMOSTASIS

Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations

(2015) Anne Godier et al.   THROMBOSIS RESEARCH

Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study

(2015) Sarah Lessire et al.   THROMBOSIS RESEARCH

Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants

(2014) Adam Cuker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013

(2013) Gilles Pernod et al.   Archives of Cardiovascular Diseases

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

(2013) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban

(2013) T. Steiner et al.   Clinical Research in Cardiology

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

(2013) Paul A. Reilly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate

(2013) Jean-Michel Dogné et al.   THROMBOSIS AND HAEMOSTASIS

Oral Anticoagulant Therapy

(2012) Walter Ageno et al.   CHEST

Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature

(2012) Jonathan Douxfils et al.   THROMBOSIS RESEARCH

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

(2010) Stuart Connolly et al.   THROMBOSIS AND HAEMOSTASIS

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

(2010) Jean Amiral et al.   THROMBOSIS AND HAEMOSTASIS